Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use

Abstract

Ceftobiprole medocaril is a fifth-generation cephalosporin (anti-MRSA cephem) with a broad spectrum of antibacterial activity. Ceftobiprole is active against gram-positive bacteria, including strains resistant to other beta-lactams, such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, as well as gram-negative bacteria such as Pseudomonas aeruginosa. The purpose of this review is to consider the mechanism of action and safety profile of ceftobiprole, as well as to summarize the results of clinical studies of the drug. Possible areas of clinical use of ceftobiprole for infections of the skin and soft tissues, complicated staphylococcal bacteremia, infective endocarditis, as well as communityacquired and nosocomial pneumonia are given. Summarizing the available information, ceftobiprole can be considered as the most important antibacterial drug for the treatment of severe pneumonia not associated with mechanical ventilation, skin and soft tissue infections, as well as a part of combination antimicrobial therapy for infective endocarditis.